Document is current
Any future updates will be listed below
-
Authors
Wang, Yongqiang
Zhang, Xiangyang
Wang, Ningning
Jiang, Huimin
Liang, Ningning
Du, Chenxi
Yin, Chunzhao
Li, Rui
Zhang, Lili
Tu, Qiaochu
Lv, Jingwen
Ma, Haoran
Xu, Xiaodong
Kong, Xinran
Chen, Xin
Liu, Guijun
Chen, Shiting
Xu, Hualing
Qin, Jun
Li, Shengxian
Tao, Yongzhen
Zeng, Shan https://orcid.org/0000-0002-0988-723X
Shen, Hong https://orcid.org/0000-0002-6456-8231
Goncalves, Marcus D.
Zhong, Shanshan https://orcid.org/0009-0002-0574-6592
Yin, Huiyong https://orcid.org/0000-0001-7049-1560
- License Information
-
More Information
Article History
Received: 20 September 2025
Revised: 11 February 2026
Accepted: 16 March 2026
First Online: 25 May 2026
Competing interests
: H.H.Y., S.S.Z., and Y.Q.W. are inventors on a patent application filed to use ebselen as a new therapeutic agent for HCC. The other authors declare that they have no competing interests.
